Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus nab-Paclitaxel and Gemcitabine in Advanced Pancreatic Cancer /PRNewswire/ — Polaris Group announced today that the first patient has been dosed in its Phase 1 trial of ADI-PEG 20 in combination with nab-paclitaxel and gemcitabine, a current first line therapy, for the treatment of advanced pancreatic cancer. Polaris Group is currently conducting clinical trials on ADI-PEG 20 in combination with cisplatin in melanoma and ovarian cancer, in combination with doxorubicin in HER2 negative breast cancer, and in combination with cisplatin and pemetrexed in malignant pleural mesothelioma and non-small cell lung carcinoma.
